Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience
| العنوان: | Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience |
|---|---|
| المؤلفون: | Aygen, Bilgehan, Demirtürk, Neşe, Yıldız, Orhan, Çelen, Mustafa Kemal, Çelik, İlhami, Barut, Şener, Ural, Önur, Batırel, Ayşe, Mıstık, Reşit, Şi̇mşek, Funda, Asan, Ali, Ersöz, Gülden Munis, Türker, Nesrin Akbaş, Bilgin, Hüseyin, Kınıklı, Sami, Karakeçili, Faruk, Zararsız, Gökmen, Günal, Özgür, Akhan, Sıla Cetin, Tulek, N., İnan, Dilara, Çaǧatay, Arif Atahan, Gürbüz, Yunus, Şener, Alper, Çelikbaş, Aysel Kocagül, Çetinkaya, Rıza Aytaç, Kadanalı, Ayten, Hakyemez, İsmail Necati, Kuruüzüm, Ziya, Özel, Selcan Arslan, Korkmaz, Pınar Yagiz, Tuna, Nazan, Saltoǧlu, Neşe, Tarakçı, Hüseyin, Uysal, Burcu, Karagöz, Ergenekon, Koçulu, Safiye, Ayaz, Celal, Güzel, Deniz Kamalak, Türkoğlu, Emine, Demir, Nazlım Aktuğ, Şimşek, Sümeyra, Kantürk, Arzu, Akça, Mustafa Özgür, Evik, Güliz, Örmen, Bahar Kopraman, Sili, Uluhan, Hatipoǧlu, Çiǧdem Ataman, Binay, Umut Devrim, Kılıç, Sırrı, Arslan, Kader, Yenilmez, Ercan, Çomoǧlu, Şenol, Koç, Meliha Meriç, Gökgöz, Altan, Dursun, Zehra Beştepe, Sümer, Şua, Heper, Yasemin, Yíldírmak, Taner T., Öztürk, Sinan, Güğül, Tuğba Demirel, Yüce, Zeynep Türe |
| المساهمون: | Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı, Çelen, Mustafa Kemal |
| المصدر: | The Turkish Journal of Gastroenterology. 31:305-317 |
| بيانات النشر: | AVES Publishing Co., 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Cyclopropanes, Male, Databases, Factual, Sustained Virologic Response, Turkey, HCV genotypes 1 and 4, Paritaprevir, Hepacivirus, Chronic hepatitis C, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, 2-Naphthylamine, Medicine, Anilides, 030212 general & internal medicine, Aged, 80 and over, Sulfonamides, Dasabuvir, virus diseases, Valine, Middle Aged, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, medicine.drug, Adult, Real-world effectiveness, medicine.medical_specialty, Genotype, Proline, Combination therapy, Lactams, Macrocyclic, Antiviral Agents, Young Adult, 03 medical and health sciences, Internal medicine, Ribavirin, Humans, Uracil, Adverse effect, Aged, Ritonavir, business.industry, Hepatitis C, Chronic, digestive system diseases, Ombitasvir, Regimen, chemistry, business |
| الوصف: | AASLD - TASL Connect Regional Meeting -- MAR 15-16, 2019 -- Istanbul, TURKEY WOS:000535263200004 PubMed: 32412901 Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) +/- dasabuvir (DSV) +/- ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r +/- DSV +/- RBV combination regimen in a real-world clinical practice. Materials and Methods: Data from HCV genotype 1 and 4 patients treated with OMV/PTV/r +/- DSV +/- RBV (n=862) in 34 centers across Turkey between April 1, 2017 and August 31, 2018 were recorded in a large national database. Demographic, clinical, and virologic data were analyzed. Results: The mean age of the patients was 55.63, and 430 patients (49.9%) were male. The majority had HCV genotype 1b infection (77.3%), and 66.2% were treatment-naive. Non-cirrhosis was present at baseline in 789 patients (91.5%). SVR12 rate was 99.1% in all patients. Seven patients had virologic failure. No significant differences were observed in SVR12 according to HCV genotypes. HCV RNA was undetectable at treatment week 4 in 90.9%, at treatment week 8 in 98.5%, and at the end of treatment (EOT) in 98.9%. SVR12 ratio was significantly higher in the non-cirrhotic patients compared to that in the compensated cirrhotic patients. Rates of adverse events (AEs) in the patients was 59.7%. Conclusion: The present real-life data of Turkey for the OBV/PTV/r +/- DSV +/- RBV treatment of patients with HCV genotype 1b, 1a, or 4 infection from 862 patients demonstrated high efficacy and a safety profile. AASLD, TASL |
| وصف الملف: | application/pdf |
| تدمد: | 2148-5607 1300-4948 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eb3dfb8799c4df7c3e6f434bc33f07dTest https://doi.org/10.5152/tjg.2020.19197Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7eb3dfb8799c4df7c3e6f434bc33f07d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21485607 13004948 |
|---|